Head and Neck

1. BrUOG 254: A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer With an Expansion Cohort For Head and Neck Cancer: A Brown University Oncology Research Group Study
   PI: Howard Safran, MD
   Sites: Rhode Island Hospital and The Miriam Hospital